The FDA Cleared the IND for Erasca Inc Product ERAS-801 for Recurrent Glioblastoma

Erasca Inc Product ERAS-801 IND Cleared by FDA

Erasca Inc (ERAS) announced that the United States Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ERAS-801, an orally available small molecule epidermal growth factor receptor (EGFR) inhibitor specifically designed to have high central nervous system (CNS) penetration for the treatment of recurrent glioblastoma multiforme (rGBM).

In the meantime, the company entered into a collaboration with the Global Coalition for Adaptive Research (GCAR) to determine the feasibility of the evaluation of ERAS-801 as part of the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial.

From Erasca Inc 

Leave a Reply